Literature DB >> 31358253

Co-occuring symptoms in older oncology patients with distinct attentional function profiles.

Inger Utne1, Borghild Løyland1, Ellen Karine Grov1, Steven Paul2, Melisa L Wong3, Yvette P Conley4, Bruce A Cooper2, Jon D Levine3, Christine Miaskowski5.   

Abstract

PURPOSE: Evaluate how subgroups of older adults with distinct attentional function profiles differ on the severity of nine common symptoms and determine demographic and clinical characteristics and symptom severity scores associated with membership in the low and moderate attentional function classes.
METHODS: Three subgroups of older oncology outpatients were identified using latent profile analysis based on Attentional Function Index (AFI) scores. Symptoms were assessed prior to the second or third cycle of CTX. Logistic regressions evaluated for associations with attentional function class membership.
RESULTS: For trait anxiety, state anxiety, depression, sleep disturbance, morning fatigue, and evening fatigue scores, differences among the latent classes followed the same pattern (low > moderate > high). For morning and evening energy, compared to high class, patients in low and moderate classes reported lower scores. For pain, compared to moderate class, patients in low class reported higher scores. In the logistic regression analysis, compared to high class, patients with lower income, higher comorbidity, higher CTX toxicity score, and higher levels of state anxiety, depression, and sleep disturbance were more likely to be in low AFI class. Compared to high class, patients with higher comorbidity and trait anxiety and lower morning energy were more likely to be in moderate AFI class.
CONCLUSIONS: Consistent with the hypothesis that an increased risk for persistent cognitive decline is likely related to a variety of physical and psychological factors, for six of the nine symptoms, a "dose response" effect was observed with higher symptom severity scores associated with a progressive decline in attentional function.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anxiety; Attentional function; Cancer; Chemotherapy; Cognitive function; Depression; Fatigue; Older adult; Pain; Sleep disturbance

Mesh:

Year:  2019        PMID: 31358253      PMCID: PMC6681665          DOI: 10.1016/j.ejon.2019.07.001

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  44 in total

Review 1.  Evaluation of the elderly with cancer.

Authors:  M Aapro; M Extermann; L Repetto
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

2.  Self-reported sleep disturbances in employed women.

Authors:  K A Lee
Journal:  Sleep       Date:  1992-12       Impact factor: 5.849

3.  Is somatic comorbidity associated with more somatic symptoms, mental distress, or unhealthy lifestyle in elderly cancer survivors?

Authors:  Ellen Karine Grov; Sophie D Fosså; Alv A Dahl
Journal:  J Cancer Surviv       Date:  2009-02-25       Impact factor: 4.442

4.  The Attentional Function Index--a self-report cognitive measure.

Authors:  Bernadine Cimprich; Moira Visovatti; David L Ronis
Journal:  Psychooncology       Date:  2011-02       Impact factor: 3.894

5.  Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.

Authors:  Arti Hurria; Carol Rosen; Clifford Hudis; Enid Zuckerman; Katherine S Panageas; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea; Mark Moasser; Chau Dang; Catherine Van Poznak; Anju Hurria; Jimmie Holland
Journal:  J Am Geriatr Soc       Date:  2006-06       Impact factor: 5.562

6.  Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan.

Authors:  Maurice M Ohayon; Mary A Carskadon; Christian Guilleminault; Michael V Vitiello
Journal:  Sleep       Date:  2004-11-01       Impact factor: 5.849

7.  Activity of daily living problems in older cancer survivors: a population-based controlled study.

Authors:  Ellen Karine Grov; Sophie D Fosså; Alv A Dahl
Journal:  Health Soc Care Community       Date:  2010-05-12

8.  MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials.

Authors:  M Extermann; M Bonetti; G W Sledge; P J O'Dwyer; P Bonomi; Al B Benson
Journal:  Eur J Cancer       Date:  2004-05       Impact factor: 9.162

9.  Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.

Authors:  Arti Hurria; Shari Goldfarb; Carol Rosen; Jimmie Holland; Enid Zuckerman; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea; Mark Moasser; Chau Dang; Catherine Van Poznak; Mark Robson; Violante E Currie; Maria Theodoulou; Larry Norton; Clifford Hudis
Journal:  Breast Cancer Res Treat       Date:  2006-03-16       Impact factor: 4.872

10.  Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study.

Authors:  M Extermann; H Chen; A B Cantor; M B Corcoran; J Meyer; E Grendys; D Cavanaugh; S Antonek; A Camarata; W E Haley; L Balducci
Journal:  Eur J Cancer       Date:  2002-07       Impact factor: 9.162

View more
  2 in total

1.  Co-occurrence of decrements in physical and cognitive function is common in older oncology patients receiving chemotherapy.

Authors:  Inger Utne; Bruce A Cooper; Christine Ritchie; Melisa Wong; Laura B Dunn; Borghild Loyland; Ellen Karine Grov; Marilyn J Hammer; Steven M Paul; Jon D Levine; Yvette P Conley; Kord M Kober; Christine Miaskowski
Journal:  Eur J Oncol Nurs       Date:  2020-08-03       Impact factor: 2.398

2.  Changes in Attentional Function in Patients From Before Through 12 Months After Breast Cancer Surgery.

Authors:  Carmen Kohler; Ming Chang; Yu-Yin Allemann-Su; Marcus Vetter; Miyeon Jung; Misook Jung; Yvette Conley; Steven Paul; Kord M Kober; Bruce A Cooper; Betty Smoot; Jon D Levine; Christine Miaskowski; Maria C Katapodi
Journal:  J Pain Symptom Manage       Date:  2020-01-15       Impact factor: 3.612

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.